Fli-1 Antibody Immunohistochemistry on an FFPE Angiosarcoma Tissue
|Intended Use||For In Vitro Diagnostic Use|
|Summary and Explanation||
Fli-1 protein, a member of the ETS family of DNA binding transcription factors, is involved in cellular proliferation and tumorigenesis. Approximately 90% of Ewing’s Sarcoma/Primitive Neuroectodermal Tumors (ES/PNET) have a specific translocation, t(11;22)(q24;q12), which results in fusion of EWS to Fli-1, and production of an EWS-Fli-1 fusion protein, which can be detected by this antibody. Among normal tissues only endothelial cells and small lymphocytes express Fli-1. Fli-1 has been found to be expressed in the great majority of vascular tumors including Angiosarcomas, Hemangioendotheliomas, Hemangiomas, and Kaposi’s Sarcomas.
It has been reported that the high sensitivity and specificity of Fli-1 is equal to or exceeds that of the established vascular markers, CD31, CD34, and Factor VIII. As the first nuclear marker of endothelium (rather than cytoplasmic or membranous), Fli-1 immunostaining also generally lacks cytoplasmic staining artifacts that are the result of endogenous peroxidases or biotin.
|Antibody Type||Mouse Monoclonal||Clone||G146-222|
|Localization||Nuclear||Control||Adrenal Gland, Fallopian Tube, Placenta, Cervix, Angiosarcoma, PNET, Hemangiomas|
|Presentation||Fli-1 is a mouse monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.|
|Note: For concentrated antibodies, please centrifuge prior to use to ensure recovery of all product.|